Healthcare Sales & Marketing Network News: Orencia

Searching News Database: Orencia

HSMN NewsFeed - 13 Dec 2023
Triveni Bio Welcomes Jeff Albers and Allison Luo to its Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 15 Dec 2021
FDA Approves First Drug to Prevent Graft Versus Host Disease
Biopharmaceuticals FDA

HSMN NewsFeed - 15 Jun 2021
Senda Biosciences Strengthens Leadership Team with Key Management Hires
Biopharmaceuticals Personnel

HSMN NewsFeed - 3 Jan 2019
Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 10 Sep 2018
Halozyme Appoints Bernadette Connaughton To Board Of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 22 Jun 2017
Biohaven Broadens Senior Leadership Team With Veteran Pharma Executives
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 21 Feb 2017
Bristol-Myers Squibb Appoints Three New Independent Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 1 Jul 2015
Celldex Therapeutics Appoints Richard Wright as Chief Commercial Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 16 Sep 2014
Dimension Therapeutics Names Annalisa Jenkins as Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 14 Jun 2013
Bristol-Myers Squibb and Simcere Enter Partnership to Co-Develop and Co-Commercialize Orencia(R) SC (abatacept) in China
Biopharmaceuticals

HSMN NewsFeed - 6 Jun 2012
ORENCIA(R) (abatacept) Demonstrates Comparable Efficacy to Humira(R) (adalimumab) in Patients with Moderate to Severe Rheumatoid Arthritis in First Head-to-Head Study of These Agents
Biopharmaceuticals

HSMN NewsFeed - 30 Jun 2011
Sheila Gujrathi, M.D. Named Chief Medical Officer of Receptos
Biopharmaceuticals Personnel

HSMN NewsFeed - 3 May 2011
Optimer Pharmaceuticals Expands Senior Management Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Nov 2010
New Magnetic Resonance Imaging (MRI) Data Show Efficacy of SIMPONI(R) in Treatment of Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 27 Sep 2010
Centocor Ortho Biotech Inc. Submits Application to FDA Seeking to Expand SIMPONI(R) Label in Treatment of Rheumatoid Arthritis
Biopharmaceuticals FDA

HSMN NewsFeed - 7 Jul 2010
European Commission Approves ORENCIA in Combination with Methotrexate for Earlier Use as First-Line Biologic after DMARD Inadequate Response for the Treatment of Rheumatoid Arthritis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 20 Oct 2009
New Data Describe Safety of Subcutaneous Administration of ORENCIA(R) (abatacept) For Patients with Moderate to Severe Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 19 Oct 2009
New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis
Biopharmaceuticals

HSMN NewsFeed - 26 Aug 2009
Updated ORENCIA(R) (abatacept) Labeling Includes Data to Support Earlier Use in Adult Patients with Moderate to Severe Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 12 Jun 2008
ORENCIA(R) (abatacept) Provided an Increasing Degree of Inhibition of Structural Damage Through Three Years in Adults with Moderate to Severe Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 8 Apr 2008
U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
Biopharmaceuticals FDA

HSMN NewsFeed - 8 Apr 2008
Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
Biopharmaceuticals Litigation

HSMN NewsFeed - 11 Feb 2008
Regulus Therapeutics Appoints Peter S. Linsley, Ph.D. as Chief Scientific Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 18 Dec 2007
FDA Approves Celltrion to Manufacture ORENCIA(R) (abatacept)
Biopharmaceuticals FDA

HSMN NewsFeed - 9 Nov 2007
Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
Biopharmaceuticals

HSMN NewsFeed - 7 Aug 2007
ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
Biopharmaceuticals FDA

HSMN NewsFeed - 15 Jun 2007
Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia(R) (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
Biopharmaceuticals

HSMN NewsFeed - 14 Nov 2006
Bristol-Myers Squibb Company Announces Promotion of Andrew Bonfield and Elliott Sigal to Executive Vice Presidents
Biopharmaceuticals Personnel

HSMN NewsFeed - 14 Nov 2006
ORENCIA(R) (abatacept) or REMICADE(R)(infliximab) Demonstrated Superior Efficacy to Placebo at Six Months With ORENCIA Demonstrating Both Durable Efficacy and a More Favorable Safety Profile Through 12 Months
Biopharmaceuticals

HSMN NewsFeed - 13 Nov 2006
ORENCIA(R) (abatacept) Data Demonstrated Improvement in Children and Adolescents With Juvenile Idiopathic Arthritis as Measured by the Validated ACR Pediatric Criteria
Biopharmaceuticals

HSMN NewsFeed - 9 Nov 2006
Two-Year Data for ORENCIA(R) (abatacept) Demonstrate Continued Efficacy in Adults With Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 1 Jun 2006
Bristol-Myers Squibb To Build New Biologics Facility In Massachusetts
Biopharmaceuticals

HSMN NewsFeed - 5 May 2006
U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) Supplemental Biologics License Application (sBLA) for Third-Party Manufacturing Facility Lonza Biologics Inc.
Biopharmaceuticals FDA

Return to NewsFeed

Additional items found! 4

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 4 additional stories matching:
Orencia
(Password required)

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.